These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 39407208)

  • 21. Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19.
    Krämer B; Knoll R; Bonaguro L; ToVinh M; Raabe J; Astaburuaga-García R; Schulte-Schrepping J; Kaiser KM; Rieke GJ; Bischoff J; Monin MB; Hoffmeister C; Schlabe S; De Domenico E; Reusch N; Händler K; Reynolds G; Blüthgen N; Hack G; Finnemann C; Nischalke HD; Strassburg CP; Stephenson E; Su Y; Gardner L; Yuan D; Chen D; Goldman J; Rosenstiel P; Schmidt SV; Latz E; Hrusovsky K; Ball AJ; Johnson JM; Koenig PA; Schmidt FI; Haniffa M; Heath JR; Kümmerer BM; Keitel V; Jensen B; Stubbemann P; Kurth F; Sander LE; Sawitzki B; ; Aschenbrenner AC; Schultze JL; Nattermann J
    Immunity; 2021 Nov; 54(11):2650-2669.e14. PubMed ID: 34592166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 infection induces mixed M1/M2 phenotype in circulating monocytes and alterations in both dendritic cell and monocyte subsets.
    Matic S; Popovic S; Djurdjevic P; Todorovic D; Djordjevic N; Mijailovic Z; Sazdanovic P; Milovanovic D; Ruzic Zecevic D; Petrovic M; Sazdanovic M; Zornic N; Vukicevic V; Petrovic I; Matic S; Karic Vukicevic M; Baskic D
    PLoS One; 2020; 15(12):e0241097. PubMed ID: 33382687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.
    Ghasemzadeh M; Ghasemzadeh A; Hosseini E
    Hum Immunol; 2022 Jan; 83(1):86-98. PubMed ID: 34583856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
    Policard M; Jain S; Rego S; Dakshanamurthy S
    Virus Res; 2021 Aug; 301():198464. PubMed ID: 34058265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergy Between NK Cells and Monocytes in Potentiating Cardiovascular Disease Risk in Severe COVID-19.
    Gunasena M; Alles M; Wijewantha Y; Mulhern W; Bowman E; Gabriel J; Kettelhut A; Kumar A; Weragalaarachchi K; Kasturiratna D; Horowitz JC; Scrape S; Pannu SR; Liu SL; Vilgelm A; Wijeratne S; Bednash JS; Demberg T; Funderburg NT; Liyanage NPM
    Arterioscler Thromb Vasc Biol; 2024 Oct; 44(10):e243-e261. PubMed ID: 38989579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-cell multiomics revealed the dynamics of antigen presentation, immune response and T cell activation in the COVID-19 positive and recovered individuals.
    Chattopadhyay P; Khare K; Kumar M; Mishra P; Anand A; Maurya R; Gupta R; Sahni S; Gupta A; Wadhwa S; Yadav A; Devi P; Tardalkar K; Joshi M; Sethi T; Pandey R
    Front Immunol; 2022; 13():1034159. PubMed ID: 36532041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination.
    Shen CF; Yen CL; Fu YC; Cheng CM; Shen TC; Chang PD; Cheng KH; Liu CC; Chang YT; Chen PL; Ko WC; Shieh CC
    Front Immunol; 2022; 13():807454. PubMed ID: 35145520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.
    Hagemann K; Riecken K; Jung JM; Hildebrandt H; Menzel S; Bunders MJ; Fehse B; Koch-Nolte F; Heinrich F; Peine S; Schulze Zur Wiesch J; Brehm TT; Addo MM; Lütgehetmann M; Altfeld M
    Eur J Immunol; 2022 Aug; 52(8):1297-1307. PubMed ID: 35416291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19.
    Kratzer B; Gattinger P; Trapin D; Ettel P; Körmöczi U; Rottal A; Stieger RB; Sehgal ANA; Feichter M; Borochova K; Tulaeva I; Grabmeier-Pfistershammer K; Tauber PA; Perkmann T; Fae I; Wenda S; Kundi M; Fischer GF; Valenta R; Pickl WF
    Allergy; 2024 Sep; 79(9):2482-2501. PubMed ID: 39003594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune characterization of a Colombian family cluster with SARS-CoV-2 infection.
    Aguilar-Jiménez W; Flórez-Álvarez L; Rincón DS; Marín-Palma D; Sánchez-Martínez A; Martínez J; Zapata MI; Loaiza JD; Cárdenas C; Guzmán F; Velilla PA; Taborda NA; Zapata W; Hernández JC; Díaz FJ; Rugeles MT
    Biomedica; 2021 Oct; 41(Sp. 2):86-102. PubMed ID: 34669281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients.
    Ni L; Cheng ML; Feng Y; Zhao H; Liu J; Ye F; Ye Q; Zhu G; Li X; Wang P; Shao J; Deng YQ; Wei P; Chen F; Qin CF; Wang G; Li F; Zeng H; Dong C
    Front Immunol; 2021; 12():603563. PubMed ID: 33603759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines
    Ma MT; Badeti S; Chen CH; Kim J; Choudhary A; Honnen B; Reichman C; Calianese D; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
    Front Immunol; 2021; 12():652223. PubMed ID: 34367128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the Long-Term Impact on Cellular Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment.
    Liu J; Yang X; Wang H; Li Z; Deng H; Liu J; Xiong S; He J; Feng X; Guo C; Wang W; Zelinskyy G; Trilling M; Sutter K; Senff T; Menne C; Timm J; Zhang Y; Deng F; Lu Y; Wu J; Lu M; Yang D; Dittmer U; Wang B; Zheng X
    mBio; 2021 Apr; 12(2):. PubMed ID: 33906918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural Killer Cell Dysfunction and Its Role in COVID-19.
    van Eeden C; Khan L; Osman MS; Cohen Tervaert JW
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32883007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence.
    La Sala L; Gandini S; Bruno A; Allevi R; Gallazzi M; Senesi P; Palano MT; Meregalli P; Longhi E; Sommese C; Luzi L; Trabucchi E
    Front Immunol; 2022; 13():798813. PubMed ID: 35237261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 activates lung epithelial cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients.
    Chen H; Liu W; Wang Y; Liu D; Zhao L; Yu J
    EBioMedicine; 2021 Aug; 70():103500. PubMed ID: 34311326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trained Immunity: An Overview and the Impact on COVID-19.
    Brueggeman JM; Zhao J; Schank M; Yao ZQ; Moorman JP
    Front Immunol; 2022; 13():837524. PubMed ID: 35251030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade.
    Lee G; Schauner R; Burke J; Borocz J; Vasana S; Sobieraj L; Giraudo M; Jackson Z; Ansari Q; Navas M; Sakr H; Wald D
    Front Immunol; 2023; 14():1022890. PubMed ID: 37483595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
    Saini P; Adeniji OS; Bordoloi D; Kinslow J; Martinson J; Parent DM; Hong KY; Koshy J; Kulkarni AJ; Zilberstein NF; Balk RA; Moy JN; Giron LB; Tracy RP; Keshavarzian A; Muthumani K; Landay A; Weiner DB; Abdel-Mohsen M
    mBio; 2023 Feb; 14(1):e0339322. PubMed ID: 36728420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural killer cells in antiviral immunity.
    Björkström NK; Strunz B; Ljunggren HG
    Nat Rev Immunol; 2022 Feb; 22(2):112-123. PubMed ID: 34117484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.